Types of Research
- (-) Remove Household Well-Being & Equity filter Household Well-Being & Equity
- (-) Remove Global & Regional Public Goods filter Global & Regional Public Goods
- (-) Remove South Asia Region and Selected Countries filter South Asia Region and Selected Countries
- (-) Remove Market & Value Chain Analysis filter Market & Value Chain Analysis
- (-) Remove Agricultural Inputs & Farm Management filter Agricultural Inputs & Farm Management
- (-) Remove Global filter Global
- (-) Remove 2011 filter 2011
- (-) Remove Food Security & Nutrition filter Food Security & Nutrition
- (-) Remove Education & Training filter Education & Training
- (-) Remove 2018 filter 2018
The private sector is the primary investor in health research and development (R&D) worldwide, with investment annual investment exceeding $150 billion, although only an estimated $5.9 billion is focused on diseases that primarily affect low and middle-income countries (LMICs) (West et al., 2017b). Pharmaceutical companies are the largest source of private spending on global health R&D focused on LMICs, providing $5.6 billion of the $5.9 billion in total private global health R&D per year. This report draws on 10-K forms filed by Pharmaceutical companies with the U.S. Securities and Exchange Commission (SEC) in the year 2016 to examine the evidence for five specific disincentives to private sector investment in drugs, vaccines and therapeutics for global health R&D: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed costs for research and manufacturing, and imperfect markets. 10-K reports follow a standard format, including a business section and a risk section which include information on financial performance, investment options, lines of research, promising acquisitions and risk factors (scientific, market, and regulatory). As a result, these filings provide a valuable source of information for analyzing how private companies discuss risks and challenges as well as opportunities associated with global health R&D targeting LMICs.
This research brief synthesizes evidence on the effects of policy incentives on agricultural productivity. The evidence discussed is primarily drawn from documents provided to EPAR by the Bill and Melinda Gates Foundation. We review the role of policy and institutions in the Asian Green Revolution, a detailed case study on how policy changes have removed smallholder productivity constraints and contributed to growth, and the theory on the connection of policy incentives to productivity growth.